Compare AbbVie Inc (ABBV) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Nomura Holdings Inc — how do they compare? AbbVie Inc trades at $254.13 (market cap $449.91B), while Nomura Holdings Inc trades at $9.41 (market cap $27.73B). The key difference: AbbVie Inc is far larger — about 16.2× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ABBV | NMR | |
|---|---|---|
Market Cap | $449.91B | $27.73B |
Sector | Health | Financials |
52-Week High | $261.07 | $9.54 |
52-Week Low | $184.85 | $6.30 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Nomura Holdings (NMR) trades at $9.42, up 3.97% with a bullish technical signal. The stock shows strong fundamentals with record annual profit of $340.74B (20.49% margin) and revenue growth to $1.66T. Recent news highlights CEO pay increase following record performance and US expansion plans. Technical indicators show bullish momentum with RSI at neutral levels, while analyst consensus leans hold-heavy with 66.7% neutral rating.
Outlook remains positive with expanding profitability and strategic acquisitions, though recent earnings misses and rising debt-to-asset ratio (26.25%) present execution risks. The stock trades at attractive valuations (P/E 12.66, P/B 1.19) but faces integration challenges from Macquarie acquisition and geopolitical uncertainties affecting growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
